Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05772546 · ClinicalTrials.gov registry record · Phase 2
Avatrombopag vs. Placebo for CIT in GI Malignancies
A Phase 2 study of Gastrointestinal Cancer and Gastrointestinal Neoplasms, sponsored by Hanny Al-Samkari, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT05772546 is a Phase 2 study of Gastrointestinal Cancer and Gastrointestinal Neoplasms that is active but no longer recruiting, run by Hanny Al-Samkari, MD. The registered enrollment target is 60 participants, below the 232-participant average among 48 other Gastrointestinal Cancer trials with a reported enrollment target (74% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05772546, a Phase 2 study of Gastrointestinal Cancer and Gastrointestinal Neoplasms, is active but no longer recruiting, sponsored by Hanny Al-Samkari, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy. The names of the study drugs involved in this study are: * Avatrombopag (a thrombopoietin receptor agonist) * Matching placebo
Conditions Studied
Interventions
- DRUG Matching Placebo
- DRUG Avatrombopag
Study Locations (4)
Florida
- University of Miami Sylvester Comprehensive Cancer Center - Miami
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Oregon
- Oregon Health and Science University Hospital - Portland
Washington
- University of Washington Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05772546
The ClinicalTrials.gov registry entry for NCT05772546 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 232-participant average among 48 other Gastrointestinal Cancer trials with a reported enrollment target (74% lower). The listed sponsor is Hanny Al-Samkari, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Gastrointestinal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Matching Placebo is the first listed.
NCT05772546 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Massachusetts, Oregon.
Frequently Asked Questions
What is clinical trial NCT05772546 about?
NCT05772546 is a clinical study titled "Avatrombopag vs. Placebo for CIT in GI Malignancies". The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy. The names of the study drugs involved in this st...
What is the current status of trial NCT05772546?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-11-01. Estimated completion is 2026-07-31.
What conditions does trial NCT05772546 study?
This clinical trial studies the following conditions: Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy Induced Thrombocytopenia.
What interventions are being tested in trial NCT05772546?
The interventions under investigation include: Matching Placebo (DRUG), Avatrombopag (DRUG).
Who is sponsoring clinical trial NCT05772546?
This trial is sponsored by Hanny Al-Samkari, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05772546 being conducted?
This trial has 4 study locations across Florida, Massachusetts, Oregon, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers
RECRUITING · Phase 2
-
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
RECRUITING · Phase 2
-
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
ACTIVE NOT RECRUITING · Phase 2
-
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
ACTIVE NOT RECRUITING · Phase 2
-
Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function
COMPLETED · Phase 2
-
CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.